Targeted Delivery of Nanoparticle Based Taxanes for Breast Cancer Treatment: A Review

Authors

  • Muhammad Farhan Hanif Faculty of Pharmacy and Alternative Medicine, Department of Pharmacy, The Islamia University of Bahawalpur 63100 Pakistan
  • Rabbiya Ahmad
  • Kanza Khalid
  • Maria Tabassum
  • Faizan Akram

DOI:

https://doi.org/10.37591/tdd.v6i3.656

Abstract

The most common type of cancers in women is breast cancer. In United States, it is the second common cause of death in women. Metastatic cancer is the advanced stage of breast cancer, which is related to the distribution of cancerous cells from breast tissues to different areas of the body. Over the past numerous years, taxanes are bound to perform a huge role in the management and treatment of numerous malignancies. Food and Drug Administration (FDA) approved Paclitaxel (PTX) and Docetaxel (DTX) clinically for the treatment of various types of cancers i.e. head/neck cancer, breast cancer, ovarian cancer, and prostate cancer. Due to poor solubility in the aqueous medium and for the targeted delivery of taxanes, different types of polymers are added along with taxanes to enhance its targeted actions and stability. The targeted delivery of nanoparticles requires specialized molecular diagnosed factors that can differentiate the tumor cells from regular cells and selectively aim the tumor cells. Recently liposomes, micelles, microemulsion, dendrimers, and solid lipid nanoparticles (SLNs) are used for targeted drug delivery of taxanes for the breast cancer treatment. PTX and DTX are the first generation taxanes that were revolutionized in the treatment of breast cancer and became famous drugs instantly. Currently, several taxanes named as larotaxel, milataxel, ortataxel, and tesetaxel are in clinical trials with combination therapy. The objective of our review is to discuss the targeted drug delivery approaches of taxane-based nanoparticles for the breast cancer treatment which is effective and has fewer side effects.

 

Keywords: breast cancer, Docetaxel, nanoparticles, Paclitaxel, targeted delivery, taxanes

 

Cite this Article

Muhammad Farhan Hanif, Rabbiya Ahmad, Kanza Khalid, Maria Tabassum, Faizan Akram. Targeted Delivery of Nanoparticle-Based Taxanes for Breast Cancer Treatment: A Review. Trends in Drug Delivery. 2019; 6(3): 36–51p.

Author Biography

  • Muhammad Farhan Hanif, Faculty of Pharmacy and Alternative Medicine, Department of Pharmacy, The Islamia University of Bahawalpur 63100 Pakistan
    Department of Pharmacy, M.Phil Scholar (Pharmaceutical Sciences)

Downloads

Published

2020-01-02

Issue

Vol. 6 No. 3 (2019)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.